AU2008232311A1

AU2008232311A1 - Methods and compositions for treating prostate cancer

Methods and compositions for treating prostate cancer Download PDF

Info

Publication number: AU2008232311A1
Authority: AU; Australia
Prior art keywords: androgen; testosterone; polypeptide; prostate; polypeptide according
Prior art date: 2007-03-27
Legal status : Abandoned

Application number

AU2008232311A

Other languages

English (en)

Inventor

Niall Corcoran

Anthony Costello

Christopher Hovens

Current Assignee

Individual

Original Assignee

Individual

Priority date

2007-03-27

Filing date

2008-03-26

Publication date

2008-10-02

2007-03-27 Priority claimed from AU2007901628A external-priority patent/AU2007901628A0/en

2008-03-26 Application filed by Individual filed Critical Individual

2008-03-26 Priority to AU2008232311A priority Critical patent/AU2008232311A1/en

2008-10-02 Publication of AU2008232311A1 publication Critical patent/AU2008232311A1/en

Status Abandoned legal-status Critical Current

Links

206010060862 Prostate cancer Diseases 0.000 title claims description 52
208000000236 Prostatic Neoplasms Diseases 0.000 title claims description 52
238000000034 method Methods 0.000 title claims description 50
239000000203 mixture Substances 0.000 title claims description 21
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 304
108090000765 processed proteins & peptides Proteins 0.000 claims description 175
229920001184 polypeptide Polymers 0.000 claims description 173
102000004196 processed proteins & peptides Human genes 0.000 claims description 172
229960003604 testosterone Drugs 0.000 claims description 152
239000003098 androgen Substances 0.000 claims description 125
230000027455 binding Effects 0.000 claims description 76
238000011282 treatment Methods 0.000 claims description 63
210000004027 cell Anatomy 0.000 claims description 56
108010080146 androgen receptors Proteins 0.000 claims description 47
102000001307 androgen receptors Human genes 0.000 claims description 46
210000002307 prostate Anatomy 0.000 claims description 34
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims description 32
229960003473 androstanolone Drugs 0.000 claims description 31
230000003247 decreasing effect Effects 0.000 claims description 31
210000005267 prostate cell Anatomy 0.000 claims description 29
108090000623 proteins and genes Proteins 0.000 claims description 29
239000008280 blood Substances 0.000 claims description 25
239000003814 drug Substances 0.000 claims description 24
102000004169 proteins and genes Human genes 0.000 claims description 24
210000004369 blood Anatomy 0.000 claims description 22
238000004519 manufacturing process Methods 0.000 claims description 20
239000000556 agonist Substances 0.000 claims description 18
108020001507 fusion proteins Proteins 0.000 claims description 17
102000039446 nucleic acids Human genes 0.000 claims description 17
108020004707 nucleic acids Proteins 0.000 claims description 17
150000007523 nucleic acids Chemical class 0.000 claims description 17
102000037865 fusion proteins Human genes 0.000 claims description 16
230000002265 prevention Effects 0.000 claims description 16
210000000064 prostate epithelial cell Anatomy 0.000 claims description 15
239000013598 vector Substances 0.000 claims description 15
230000012010 growth Effects 0.000 claims description 14
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 13
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 12
102100024028 Progonadoliberin-1 Human genes 0.000 claims description 12
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 12
239000003446 ligand Substances 0.000 claims description 12
101000775732 Homo sapiens Androgen receptor Proteins 0.000 claims description 8
101000928259 Homo sapiens NADPH:adrenodoxin oxidoreductase, mitochondrial Proteins 0.000 claims description 8
102000046818 human AR Human genes 0.000 claims description 8
230000001419 dependent effect Effects 0.000 claims description 7
108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 claims description 6
239000005557 antagonist Substances 0.000 claims description 6
102000034755 Sex Hormone-Binding Globulin Human genes 0.000 claims description 4
108010089417 Sex Hormone-Binding Globulin Proteins 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 description 44
210000002966 serum Anatomy 0.000 description 38
241000699670 Mus sp. Species 0.000 description 31
150000003431 steroids Chemical class 0.000 description 27
230000000694 effects Effects 0.000 description 22
235000018102 proteins Nutrition 0.000 description 22
108091006020 Fc-tagged proteins Proteins 0.000 description 21
241001465754 Metazoa Species 0.000 description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
108020004414 DNA Proteins 0.000 description 16
239000003795 chemical substances by application Substances 0.000 description 16
201000010099 disease Diseases 0.000 description 16
238000002347 injection Methods 0.000 description 16
239000007924 injection Substances 0.000 description 16
230000007423 decrease Effects 0.000 description 14
229940088597 hormone Drugs 0.000 description 13
239000005556 hormone Substances 0.000 description 13
150000001875 compounds Chemical class 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
239000000243 solution Substances 0.000 description 12
230000001225 therapeutic effect Effects 0.000 description 12
238000002474 experimental method Methods 0.000 description 11
230000004044 response Effects 0.000 description 11
108010088751 Albumins Proteins 0.000 description 10
102000009027 Albumins Human genes 0.000 description 10
238000003556 assay Methods 0.000 description 10
229940079593 drug Drugs 0.000 description 10
102000014914 Carrier Proteins Human genes 0.000 description 9
230000002411 adverse Effects 0.000 description 9
239000000051 antiandrogen Substances 0.000 description 9
201000011510 cancer Diseases 0.000 description 9
-1 progestin cyproterone acetate Chemical class 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 8
230000002280 anti-androgenic effect Effects 0.000 description 8
108091008324 binding proteins Proteins 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
239000013612 plasmid Substances 0.000 description 8
230000004083 survival effect Effects 0.000 description 8
238000012360 testing method Methods 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 8
238000010317 ablation therapy Methods 0.000 description 7
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 7
229960000978 cyproterone acetate Drugs 0.000 description 7
239000000824 cytostatic agent Substances 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
230000008901 benefit Effects 0.000 description 6
229940127089 cytotoxic agent Drugs 0.000 description 6
239000002254 cytotoxic agent Substances 0.000 description 6
231100000599 cytotoxic agent Toxicity 0.000 description 6
239000012091 fetal bovine serum Substances 0.000 description 6
XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 6
229960002653 nilutamide Drugs 0.000 description 6
238000001959 radiotherapy Methods 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
239000000523 sample Substances 0.000 description 6
LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 5
241001529936 Murinae Species 0.000 description 5
241000699660 Mus musculus Species 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000004913 activation Effects 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
229940030486 androgens Drugs 0.000 description 5
238000013459 approach Methods 0.000 description 5
229960000997 bicalutamide Drugs 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
238000002648 combination therapy Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
238000005259 measurement Methods 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
230000009467 reduction Effects 0.000 description 5
150000003839 salts Chemical group 0.000 description 5
208000002491 severe combined immunodeficiency Diseases 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
230000001629 suppression Effects 0.000 description 5
210000001550 testis Anatomy 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
241000894006 Bacteria Species 0.000 description 4
108010017384 Blood Proteins Proteins 0.000 description 4
102000004506 Blood Proteins Human genes 0.000 description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 4
230000004075 alteration Effects 0.000 description 4
238000010171 animal model Methods 0.000 description 4
239000002585 base Substances 0.000 description 4
DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 4
239000000969 carrier Substances 0.000 description 4
210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
210000002919 epithelial cell Anatomy 0.000 description 4
210000004907 gland Anatomy 0.000 description 4
230000028993 immune response Effects 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 4
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 4
229960004338 leuprorelin Drugs 0.000 description 4
108020001756 ligand binding domains Proteins 0.000 description 4
206010061289 metastatic neoplasm Diseases 0.000 description 4
239000003956 nonsteroidal anti androgen Substances 0.000 description 4
238000011580 nude mouse model Methods 0.000 description 4
229960002378 oftasceine Drugs 0.000 description 4
239000000047 product Substances 0.000 description 4
230000028327 secretion Effects 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
210000003462 vein Anatomy 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108010069236 Goserelin Proteins 0.000 description 3
108010000817 Leuprolide Proteins 0.000 description 3
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 3
102000006467 TATA-Box Binding Protein Human genes 0.000 description 3
108010044281 TATA-Box Binding Protein Proteins 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
210000001015 abdomen Anatomy 0.000 description 3
230000003187 abdominal effect Effects 0.000 description 3
239000000654 additive Substances 0.000 description 3
210000004100 adrenal gland Anatomy 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000000601 blood cell Anatomy 0.000 description 3
230000037396 body weight Effects 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
239000003610 charcoal Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000004891 communication Methods 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
239000003651 drinking water Substances 0.000 description 3
235000020188 drinking water Nutrition 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
229960002074 flutamide Drugs 0.000 description 3
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 3
230000006870 function Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
231100000226 haematotoxicity Toxicity 0.000 description 3
230000002489 hematologic effect Effects 0.000 description 3
210000003016 hypothalamus Anatomy 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
201000001881 impotence Diseases 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
229960004768 irinotecan Drugs 0.000 description 3
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000036210 malignancy Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
238000013439 planning Methods 0.000 description 3
239000002243 precursor Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000011472 radical prostatectomy Methods 0.000 description 3
238000012552 review Methods 0.000 description 3
210000001625 seminal vesicle Anatomy 0.000 description 3
238000009097 single-agent therapy Methods 0.000 description 3
230000003637 steroidlike Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
229960000303 topotecan Drugs 0.000 description 3
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
238000001890 transfection Methods 0.000 description 3
238000012384 transportation and delivery Methods 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
210000003932 urinary bladder Anatomy 0.000 description 3
201000010653 vesiculitis Diseases 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
239000002677 5-alpha reductase inhibitor Substances 0.000 description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
108010082126 Alanine transaminase Proteins 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
108010006654 Bleomycin Proteins 0.000 description 2
125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
208000010228 Erectile Dysfunction Diseases 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
102000006395 Globulins Human genes 0.000 description 2
108010044091 Globulins Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
108090000144 Human Proteins Proteins 0.000 description 2
102000003839 Human Proteins Human genes 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229940123237 Taxane Drugs 0.000 description 2
108010050144 Triptorelin Pamoate Proteins 0.000 description 2
206010046543 Urinary incontinence Diseases 0.000 description 2
108010084455 Zeocin Proteins 0.000 description 2
238000002679 ablation Methods 0.000 description 2
229940022663 acetate Drugs 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
125000003275 alpha amino acid group Chemical group 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
229910052921 ammonium sulfate Inorganic materials 0.000 description 2
235000011130 ammonium sulphate Nutrition 0.000 description 2
238000009167 androgen deprivation therapy Methods 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
230000001857 anti-mycotic effect Effects 0.000 description 2
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
239000002543 antimycotic Substances 0.000 description 2
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000002146 bilateral effect Effects 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000008512 biological response Effects 0.000 description 2
229960001561 bleomycin Drugs 0.000 description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
229960004562 carboplatin Drugs 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
229960004630 chlorambucil Drugs 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
229960004316 cisplatin Drugs 0.000 description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
229940001468 citrate Drugs 0.000 description 2
230000007012 clinical effect Effects 0.000 description 2
238000002591 computed tomography Methods 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
238000010276 construction Methods 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
230000006378 damage Effects 0.000 description 2
229960000975 daunorubicin Drugs 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000001934 delay Effects 0.000 description 2
230000000779 depleting effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
229960003668 docetaxel Drugs 0.000 description 2
238000004980 dosimetry Methods 0.000 description 2
229960004679 doxorubicin Drugs 0.000 description 2
230000000459 effect on growth Effects 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
229940073621 enbrel Drugs 0.000 description 2
229960001904 epirubicin Drugs 0.000 description 2
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
229960004039 finasteride Drugs 0.000 description 2
DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000004927 fusion Effects 0.000 description 2
239000003163 gonadal steroid hormone Substances 0.000 description 2
229960003690 goserelin acetate Drugs 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
239000000710 homodimer Substances 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000005462 in vivo assay Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
229960003299 ketamine Drugs 0.000 description 2
229960004125 ketoconazole Drugs 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
230000007774 longterm Effects 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
108010082117 matrigel Proteins 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
229960001924 melphalan Drugs 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
229960004857 mitomycin Drugs 0.000 description 2
229960001156 mitoxantrone Drugs 0.000 description 2
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000035772 mutation Effects 0.000 description 2
BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
238000011474 orchiectomy Methods 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229960003531 phenolsulfonphthalein Drugs 0.000 description 2
CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
201000005825 prostate adenocarcinoma Diseases 0.000 description 2
230000005855 radiation Effects 0.000 description 2
229940116176 remicade Drugs 0.000 description 2
238000011160 research Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
230000000630 rising effect Effects 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
230000011664 signaling Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000011121 sodium hydroxide Nutrition 0.000 description 2
241000894007 species Species 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
229960004824 triptorelin Drugs 0.000 description 2
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
230000002792 vascular Effects 0.000 description 2
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
229960001600 xylazine Drugs 0.000 description 2
AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
ZKEZEXYKYHYIMQ-UHFFFAOYSA-N 3-cyclohexyl-1-(2-morpholin-4-yl-2-oxoethyl)-2-phenyl-1h-indole-6-carboxylic acid Chemical compound C=1C=CC=CC=1C=1N(CC(=O)N2CCOCC2)C2=CC(C(=O)O)=CC=C2C=1C1CCCCC1 ZKEZEXYKYHYIMQ-UHFFFAOYSA-N 0.000 description 1
PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
108020003589 5' Untranslated Regions Proteins 0.000 description 1
WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
206010006298 Breast pain Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241001432959 Chernes Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
102100037101 Deoxycytidylate deaminase Human genes 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
102400001047 Endostatin Human genes 0.000 description 1
108010079505 Endostatins Proteins 0.000 description 1
108010008165 Etanercept Proteins 0.000 description 1
206010017912 Gastroenteritis radiation Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000006580 General Transcription Factors Human genes 0.000 description 1
108010008945 General Transcription Factors Proteins 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
206010053759 Growth retardation Diseases 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
101000955042 Homo sapiens Deoxycytidylate deaminase Proteins 0.000 description 1
101000703436 Homo sapiens Sex hormone-binding globulin Proteins 0.000 description 1
206010071119 Hormone-dependent prostate cancer Diseases 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010020591 Hypercapnia Diseases 0.000 description 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
206010021639 Incontinence Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
239000005517 L01XE01 - Imatinib Substances 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
206010064912 Malignant transformation Diseases 0.000 description 1
208000006662 Mastodynia Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
108090000143 Mouse Proteins Proteins 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
108010077850 Nuclear Localization Signals Proteins 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
108091005682 Receptor kinases Proteins 0.000 description 1
235000011449 Rosa Nutrition 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
108020004459 Small interfering RNA Proteins 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000010513 Stupor Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
239000008049 TAE buffer Substances 0.000 description 1
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
102000002938 Thrombospondin Human genes 0.000 description 1
108060008245 Thrombospondin Proteins 0.000 description 1
IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
206010046555 Urinary retention Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
210000003815 abdominal wall Anatomy 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000003470 adrenal cortex hormone Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
229940050528 albumin Drugs 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229960003437 aminoglutethimide Drugs 0.000 description 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
239000003263 anabolic agent Substances 0.000 description 1
229940124325 anabolic agent Drugs 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
229960002932 anastrozole Drugs 0.000 description 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
239000003936 androgen receptor antagonist Substances 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000011319 anticancer therapy Methods 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003101 antineoplastic hormone agonist and antagonist Substances 0.000 description 1
238000005899 aromatization reaction Methods 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
229940120638 avastin Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000002352 blister Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
238000007469 bone scintigraphy Methods 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
235000010338 boric acid Nutrition 0.000 description 1
238000002725 brachytherapy Methods 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000009702 cancer cell proliferation Effects 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
231100000060 cardiovascular toxicity Toxicity 0.000 description 1
230000007681 cardiovascular toxicity Effects 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
108700008462 cetrorelix Proteins 0.000 description 1
SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
229960003230 cetrorelix Drugs 0.000 description 1
229960005395 cetuximab Drugs 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
230000007665 chronic toxicity Effects 0.000 description 1
231100000160 chronic toxicity Toxicity 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000003271 compound fluorescence assay Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002447 crystallographic data Methods 0.000 description 1
GOHCTCOGYKAJLZ-UHFFFAOYSA-N ctep Chemical compound CC=1N(C=2C=CC(OC(F)(F)F)=CC=2)C(C)=NC=1C#CC1=CC=NC(Cl)=C1 GOHCTCOGYKAJLZ-UHFFFAOYSA-N 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
238000011018 current good manufacturing practice Methods 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960003843 cyproterone Drugs 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
238000011393 cytotoxic chemotherapy Methods 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
229960000452 diethylstilbestrol Drugs 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
229960004199 dutasteride Drugs 0.000 description 1
JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
239000012636 effector Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229930013356 epothilone Natural products 0.000 description 1
HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
229960001433 erlotinib Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
229960000255 exemestane Drugs 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000004744 fabric Substances 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
229940080856 gleevec Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
239000000745 gonadal hormone Substances 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 1
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
229960002913 goserelin Drugs 0.000 description 1
239000003966 growth inhibitor Substances 0.000 description 1
201000000079 gynecomastia Diseases 0.000 description 1
230000035876 healing Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
102000036124 hormone binding proteins Human genes 0.000 description 1
108091011044 hormone binding proteins Proteins 0.000 description 1
102000048863 human SHBG Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229940048921 humira Drugs 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
235000011167 hydrochloric acid Nutrition 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000009848 hypophosphorylation Effects 0.000 description 1
229960000908 idarubicin Drugs 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
229940027941 immunoglobulin g Drugs 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
229940032219 immunotherapy vaccine Drugs 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
GKOZUEZYRPOHIO-IGMARMGPSA-N iridium-192 Chemical compound [192Ir] GKOZUEZYRPOHIO-IGMARMGPSA-N 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229960003881 letrozole Drugs 0.000 description 1
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000036212 malign transformation Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
229960004616 medroxyprogesterone Drugs 0.000 description 1
FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
239000012528 membrane Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
229960001293 methylprednisolone acetate Drugs 0.000 description 1
PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
229960004719 nandrolone Drugs 0.000 description 1
NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000004977 neurovascular bundle Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
102000006255 nuclear receptors Human genes 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
229960001756 oxaliplatin Drugs 0.000 description 1
DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
229960002087 pertuzumab Drugs 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000035409 positive regulation of cell proliferation Effects 0.000 description 1
238000012809 post-inoculation Methods 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
238000009163 protein therapy Methods 0.000 description 1
210000003689 pubic bone Anatomy 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
201000007608 radiation cystitis Diseases 0.000 description 1
208000020624 radiation proctitis Diseases 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
229960004622 raloxifene Drugs 0.000 description 1
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
229960004432 raltitrexed Drugs 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
102000027426 receptor tyrosine kinases Human genes 0.000 description 1
108091008598 receptor tyrosine kinases Proteins 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
210000002796 renal vein Anatomy 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
210000000574 retroperitoneal space Anatomy 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000002955 secretory cell Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
231100000004 severe toxicity Toxicity 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
150000003384 small molecules Chemical group 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
239000011655 sodium selenate Substances 0.000 description 1
235000018716 sodium selenate Nutrition 0.000 description 1
229960001881 sodium selenate Drugs 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
229960003787 sorafenib Drugs 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
210000001562 sternum Anatomy 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
230000010009 steroidogenesis Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
229910052712 strontium Inorganic materials 0.000 description 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000007474 system interaction Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940120982 tarceva Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
230000002381 testicular Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
229960001196 thiotepa Drugs 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
229960004167 toremifene citrate Drugs 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
206010044412 transitional cell carcinoma Diseases 0.000 description 1
230000014616 translation Effects 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
230000004222 uncontrolled growth Effects 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
231100000342 urinary toxicity Toxicity 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000001177 vas deferen Anatomy 0.000 description 1
LLDWLPRYLVPDTG-UHFFFAOYSA-N vatalanib succinate Chemical compound OC(=O)CCC(O)=O.C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 LLDWLPRYLVPDTG-UHFFFAOYSA-N 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
238000001262 western blot Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 1